Download Product Profiles: Autism Spectrum Disorders – Growing Interest in Underserved Market Brochure

Brochure
More information from http://www.researchandmarkets.com/reports/2154037/
Product Profiles: Autism Spectrum Disorders – Growing Interest in
Underserved Market
Description:
This report reviews current brands indicated for the treatment of autism spectrum disorders (ASDs) and key
drugs in clinical development for the potential treatment of these conditions.
Over the past 6 years, three major events have impacted the autism spectrum disorders market. In 2006,
Risperdal became the first drug to receive approval from the US FDA for the symptomatic treatment of
irritability in children and adolescents with ASDs. Later, in 2009, the FDA approved Abilify for the same
indication. In 2008, generic risperidone launched following Risperdal's US patent expiry.
Scope
- Overview of marketed and pipeline drugs in clinical development for autism spectrum disorders.
- Analysis of the market positioning of each product approved for the treatment of autism spectrum
disorders.
- Assessment of the strengths, weaknesses, opportunities, and threats for marketed and late-stage pipeline
candidates.
- Summary of the clinical and commercial attractiveness for each of the marketed products.
- Insight from key opinion leaders on marketed and pipeline products.
Highlights
- Risperdal and Abilify are the only two products approved for the treatment of autism spectrum disorders
(ASDs). Both of these atypical antipsychotics are indicated for the management of irritability symptoms
associated with ASDs in the US. Due to the failure of these drugs to address the core symptoms of ASDs,
many other drugs are used off-label.
- Abilify is the most recent entrant to the ASDs market, having received US Food and Drug Administration
(FDA) approval in November 2009. The drug's partial agonism of dopamine receptors unique mechanism of
action is considered a key differentiating factor, producing a superior side-effect profile compared to other
atypical antipsychotics.
- To date, none of the four late-stage pipeline candidates for autism spectrum disorders has publically
presented the late-stage Phase II or Phase III trial data necessary for the clinical assessment of these
compounds.
reasons to Purchase
- What are the key differentiating features of approved therapies for the treatment of autism spectrum
disorders?
- How do key opinion leaders perceive available treatments for autism spectrum disorders?
- What opportunities are there for existing players in the autism spectrum disorders market to increase their
market share?
- What is the development status of current pipeline candidates?
- What clinical trial designs are current pipeline candidates following? What do pipeline candidates need to
demonstrate in order to be successful?
Contents:
OVERVIEW
- Catalyst
- Summary
EXECUTIVE SUMMARY
- Update details: April 2012
- Strategic scoping and focus
- Datamonitor key findings
- Related reports
MARKET DEFINITION AND OVERVIEW
- Market definition
- Product overview
MARKETED PRODUCT PROFILES
- Abilify (aripiprazole; Bristol-Myers Squibb/Otsuka Pharmaceuticals)
- - Drug profile
- - Development overview
- - SWOT analysis
- - Product positioning
- - Clinical and commercial attractiveness
- Risperdal (risperidone; Johnson & Johnson)
- - Drug profile
- - Development overview
- - SWOT analysis
- - Product positioning
- - Clinical and commercial attractiveness
PIPELINE PRODUCT PROFILES
- CM-AT (Curemark)
- - Drug profile
- - Development overview
- - SWOT analysis
- AT001 (fluoxetine; Autism Therapeutics)
- - Drug profile
- - Development overview
- - SWOT analysis
- Other drugs in clinical development for autism spectrum disorders
- - STX-209 (arbaclofen; Seaside Therapeutics)
- - Memantine hydrochloride (Forest Laboratories/Merz)
- - UCB-MNC (umbilical cord blood mononuclear stem cells; Beike Biotech)
- - Carbetocin (Kyalin Bioscience)
- - RG-7314 (Roche)
- - RO-5028442 (Roche)
BIBLIOGRAPHY
- Journal papers
- Websites
- Datamonitor reports
APPENDIX
- PharmaVitae Explorer database
- Contributing experts
- Conferences attended
- Report methodology
TABLES
Table: Summary of therapeutic classes in autism spectrum disorders by A natomical Therapeutic Chemical
code, 2012
Table: Summary of the ICD-10 codes used to derive drugs indicated and in clinical development for autism
spectrum disorders
Table: Key marketed products for autism spectrum disorders, June 2012
Table: Key pipeline products for autism spectrum disorders, April 2012
Table: Abilify (aripiprazole; Otsuka/Bristol-Myers Squibb) – drug profile for autism spectrum disorders, 2012
Table: Overview of pivotal and long-term trials conducted for Abilify (aripiprazole) in autism spectrum
disorders
Table: Overview of side effects associated with Abilify in two pivotal Phase III clinical trials in autism
spectrum disorders
Table: Datamonitor drug assessment summary of Abilify (aripiprazole; Bristol-Myers Squibb/Otsuka
Pharmaceuticals) for autism spectrum disorders, 2012
Table: Risperdal (risperidone; Johnson & Johnson) – drug profile for autism spectrum disorders, 2012
Table: Overview of pivotal trials conducted for Risperdal in the treatment of autism spectrum disorders
Table: Overview of side effects reported in two pivotal Phase III clinical trials of Risperdal in autism spectrum
disorders
Table: Datamonitor drug assessment summary of Risperdal (risperidone; Johnson & Johnson) for autism
spectrum disorders, 2011
Table: CM-AT (Curemark) – drug profile, 2012
Table: Phase III clinical trial of CM-AT in the treatment of core symptoms of autism spectrum disorders, 2012
Table: Phase III open-label extension study of CM-AT in the treatment of core symptoms of autism spectrum
disorders, 2012
Table: AT001 (fluoxetine; Autism Therapeutics) – drug profile, 2012
Table: Overview of Phase III trials conducted for fluoxetine in the treatment of autism spectrum disorders
Table: STX-209 (arbaclofen; Seaside Therapeutics) – drug profile, 2012
Table: Memantine hydrochloride (Forest Laboratories/Merz) – drug profile, 2012
Table: Phase II clinical trial of memantine hydrochloride in the treatment of children with autism spectrum
disorders, 2012
Table: An early Phase II clinical trial of memantine hydrochloride in the treatment of adults with autism
spectrum disorders, 2012
Table: UCB-MNC (Beike Biotech) – drug profile, 2012
Table: Carbetocin (Kyalin Bioscience) – drug profile, 2012
FIGURES
Figure: Abilify (aripiprazole; Otsuka Pharmaceuticals/Bristol-Myers Squibb) SWOT analysis in autism
spectrum disorders, 2011
Figure: Datamonitor drug assessment summary of Abilify (aripiprazole; Bristol-Myers Squibb/Otsuka
Pharmaceuticals) for autism spectrum disorders, 2012
Figure: Risperdal (risperidone; Johnson & Johnson) SWOT analysis in autism spectrum disorders, 2012
Figure: Datamonitor drug assessment summary of Risperdal (risperidone; Johnson & Johnson) for autism
spectrum disorders, 2011
Figure: CM-AT (Curemark) SWOT analysis in autism spectrum disorders, 2012
Figure: AT001 (fluoxetine; Autism Therapeutics) SWOT analysis in autism spectrum disorders, 2012
Figure: Phase II clinical trial of STX-209 for autism spectrum disorders
Figure: Ongoing late Phase II clinical trial of STX-209 for autism spectrum disorders
Figure: The PharmaVitae Explorer
Ordering:
Order Online - http://www.researchandmarkets.com/reports/2154037/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Page 1 of 2
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from
USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/
Order Information
Please verify that the product information is correct and select the format(s) you require.
Product Name:
Product Profiles: Autism Spectrum Disorders – Growing Interest in Underserved
Market
Web Address:
http://www.researchandmarkets.com/reports/2154037/
Office Code:
SCHL3FA7
Product Formats
Please select the product formats and quantity you require:
Quantity
Electronic (PDF) Single User:
USD 3800
Electronic (PDF) Enterprisewide:
USD 9500
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title:
First Name:
Mr
Mrs
Dr
Miss
Last Name:
Email Address: *
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:
* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Ms
Prof
Page 2 of 2
Payment Information
Please indicate the payment method you would like to use by selecting the appropriate box.
Pay by credit card:
You will receive an email with a link to a secure webpage to enter your
credit card details.
Pay by check:
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.
Pay by wire transfer:
Please transfer funds to:
Account number
833 130 83
Sort code
98-53-30
Swift code
ULSBIE2D
IBAN number
IE78ULSB98533083313083
Bank Address
Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at
http://www.researchandmarkets.com/info/terms.asp
Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World